Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03058783 | Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects | PHASE3 | COMPLETED | 328 | — | — | Aug 14, 2018 | May 12, 2020 | May 8, 2023 | 1 | United States |
| NCT03002571 | Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301) | PHASE3 | COMPLETED | 338 | — | — | Jul 24, 2018 | Apr 14, 2020 | May 8, 2023 | 1 | United States |
Investigator Global Assessment (IGA) was determined based on evaluator-blinded evaluations of the inflammatory signs of atopic dermatitis. Evaluations were scored using a 5-point scale from clear (0) to severe (4), with higher numbers indicating worse scores.
| Arm | Type | Description |
|---|---|---|
| IDP-124 Lotion | EXPERIMENTAL | IDP-124 Lotion, twice-daily application |
| IDP-124 Vehicle Lotion | ACTIVE_COMPARATOR | IDP-124 Vehicle Lotion, twice-daily application |
| Name | Type | Description |
|---|---|---|
| IDP-124 Lotion | DRUG | IDP-124 Lotion, twice-daily application |
| IDP-124 Vehicle Lotion | DRUG | IDP-124 Vehicle Lotion, twice-daily application |
Inclusion Criteria: * Male or female at least 2 years of age and older * Written and verbal informed consent must be obtained; subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent durin...